Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0317841 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Basile Chrétien und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Medicine and Clinical Research, Section of Biostatistics, Nagoya University Graduate School of Medicine, Aichi, Japan. Hauptthemen laut MEDLINE: Hypertension, Selective Serotonin Reuptake Inhibitors, Pharmacovigilance. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Recent literature has reported instances of drug associated with hypertension with serotonin reuptake inhibitors (SRIs). Nonetheless, the association between SRIs and hypertension development is the subject of ongoing debate. It remains uncertain whether this is indicative of a class effect, and if dose-effect exist. To investigate the potential class effect associating SRIs with hypertension reporting, we utilized real-world data from VigiBase®, the World Health Organization (WHO) pharmacovigilance database.
Methods
We conducted an updated disproportionality analysis within VigiBase® to identify a signal of hypertension reporting with individual SRIs by calculating adjusted reporting odds ratios (aRORs) within a multivariate case/non-case study design. Additionally, we explored the presence of a dose-effect relationship.
Results
The database contained 13,682 reports of SRI associated with hypertension (2.2%), predominantly in women (70.0%). Hypertension was most reported in the 45-64 years old age group (44.8%). A total of 3,879 cases were associated with sertraline, 2,862 with fluoxetine, 2,516 with citalopram, 2,586 with escitalopram, 2,441 with paroxetine, 201 with fluvoxamine and 8 with zimeldine. A significant ROR was observed for all SRIs in both univariate (RORs ranging from 1.39 to 1.54) and multivariable analyses (aRORs ranging from 1.16 to 1.40) after adjustments for age group, sex, concurrent antihypertensive medication and drugs knowns to induce hypertension, except for fluvoxamine and zimeldine. No dose-response relationship was identified.
Conclusion
This investigation, conducted under real life conditions, unveils a notable pharmacovigilance safety signal associating SRI usage with hypertension reporting. No dose-response effect was detectable. Further longitudinal studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Advanced Medicine and Clinical Research, Section of Biostatistics, Nagoya University Graduate School of Medicine, Aichi, Japan.
- Normandie Univ, UNICAEN, Department of general practice, Caen, France.
- CHU Caen, Pharmacology Department, Caen, France.
- Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE, Caen, France.
ORCID-Profile: Basile Chrétien, Nishida Kazuki, Xavier Humbert
Zitieren
APA
Chrétien, B., Rabiaza, A., Kazuki, N., Fedrizzi, S., Sassier, M., Dolladille, C., Alexandre, J., & Humbert, X. (2025). Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency. PLOS ONE. https://doi.org/10.1371/journal.pone.0317841
Vancouver
Chrétien B, Rabiaza A, Kazuki N, Fedrizzi S, Sassier M, Dolladille C, et al. Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency. PLOS ONE. 2025. doi:10.1371/journal.pone.0317841
BibTeX
@article{Chrtien2025,
author = {Chrétien, Basile and Rabiaza, Andry and Kazuki, Nishida and Fedrizzi, Sophie and Sassier, Marion and Dolladille, Charles and Alexandre, Joachim and Humbert, Xavier},
title = {Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0317841}
}
EUVIMED